ethyl (R)-3-(4-aminophenyl)butanoate | 288580-48-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl (R)-3-(4-aminophenyl)butanoate
• 英文别名: ethyl (R) 3-(4-aminophenyl)butyrate；ethyl (3R)-3-(4-aminophenyl)butanoate
• CAS: 288580-48-3
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: JMMZYEHPYZGZOK-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2-methylphenylamino)-6-benzoxazolylacetic acid 、 ethyl (R)-3-(4-aminophenyl)butanoate 在 sodium hydroxide 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 为溶剂， 生成 3(R)-{4-[2-(2-o-tolylaminobenzoxazol-6-yl)acetylamino]phenyl}butanoic acid
  参考文献：
  名称：

  Substituted bicyclic compounds

  摘要：

  该发明涉及式(Ia)的生理活性化合物： 其中R1是可选择取代的芳基或可选择取代的杂环芳基；R2是氢、卤素、低碳基或低烷氧基；R3是烷基、烯基或炔基；R5是氢或低碳基；L2是可选择取代的烷基或烯基；Y是羧基；Z1是NR5；以及相应的N-氧化物，它们的前药；以及这些化合物及其N-氧化物和前药的药学上可接受的盐和溶剂化合物（例如水合物）。 这些化合物具有有价值的药理特性，特别是调节VCAM-1和纤维连接蛋白与整合素VLA-4（α4β1）相互作用的能力。

  公开号：

  US20020137782A1
• 作为产物：
  描述：

  ethyl 3(R)-(4-nitrophenyl)butanoate 在 palladium on charcoal ammonium formate 作用下， 以 乙醇 为溶剂， 生成 ethyl (R)-3-(4-aminophenyl)butanoate
  参考文献：
  名称：

  Substituted bicyclic compounds

  摘要：

  该发明涉及式(Ia)的生理活性化合物： 其中R1是可选择取代的芳基或可选择取代的杂环芳基；R2是氢、卤素、低碳基或低烷氧基；R3是烷基、烯基或炔基；R5是氢或低碳基；L2是可选择取代的烷基或烯基；Y是羧基；Z1是NR5；以及相应的N-氧化物，它们的前药；以及这些化合物及其N-氧化物和前药的药学上可接受的盐和溶剂化合物（例如水合物）。 这些化合物具有有价值的药理特性，特别是调节VCAM-1和纤维连接蛋白与整合素VLA-4（α4β1）相互作用的能力。

  公开号：

  US20020137782A1

文献信息

• Substituted ureas
  申请人：——

  公开号：US20020082255A1

  公开（公告）日：2002-06-27

  The invention is directed to physiologically active compounds of general formula (I): 1 wherein R 1 is lower alkyl, R 2 is aryl, arylalkyl, heteroaryl or heteroarylalkyl, or R 1 and R 2 together with the nitrogen atom to which they are attached form a cyclic amine, Ar 1 is aryldiyl or heteroaryldiyl, Ar 2 is optionally substituted phenylene or heteroaryldiyl, L 1 is an a —R 5 —R 6 — linkage where R 5 is alkylene, alkenylene or alkynylene and R 6 is a direct bond, cycloalkylene, heterocycloalkylene, arylene, heteroaryldiyl, —C(═Z 1 )—NR 4 —, —NR 4 —C(═Z 1 )—, —Z 1 —, —C(═O)—, —C(═NOR 4 )—, —NR 4 —, —NR 4 —C(═Z 1 )—NR 4 —, —SO 2 —NR 4 —, —NR 4 —SO 2 —, —O—C(═O)—, —C(═O)—O—, —NR 4 —C(═O)—O— or —O—C(═O)—NR 4 —, L 2 is a direct bond, an optionally substituted alkylene, alkenylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or aryldiyl linkage, a —[C(═O)—N(R 9 )—C(R 4 )(R 10 )] p — linkage, a —Z 3 —R 11 — linkage, a —C(═O)—CH 2 —C(═O)— linkage or a —R 11 —Z 3 —R 11 — linkage, and Y is carboxy or an acid bioisostere; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (&agr;4&bgr;1).

  本发明涉及通式（I）的生理活性化合物：其中R1为较低的烷基，R2为芳基，芳基烷基，杂芳基或杂芳基烷基，或者R1和R2与它们连接的氮原子一起形成环状胺，Ar1为芳基二基或杂芳基二基，Ar2为可选的取代苯基或杂芳基二基，L1为a-R5-R6-连接，其中R5为烷基，烯基或炔基，R6为直接键，环状烷基，杂环烷基，芳基，杂芳基二基，-C（═Z1）-NR4-，-NR4-C（═Z1）-，-Z1-，-C（═O）-，-C（═NOR4）-，-NR4-，-NR4-C（═Z1）-NR4-，-SO2-NR4-，-NR4-SO2-，-O-C（═O）-，-C（═O）-O-，-NR4-C（═O）-O-或-O-C（═O）-NR4-，L2为直接键，可选的取代烷基，烯基，炔基，环状烯基，环状烷基，杂芳基二基，杂环烷基或芳基二基连接，-C（═O）-N（R9）-C（R4）（R10）p-连接，-Z3-R11-连接，-C（═O）-CH2-C（═O）-连接或-R11-Z3-R11-连接，Y为羧基或酸类生物异构体；以及相应的N-氧化物和它们的前药；以及这些化合物及其N-氧化物和前药的药学上可接受的盐和溶剂（例如水合物）。这些化合物具有有价值的药理学性质，特别是调节VCAM-1和纤维连接蛋白与整合素VLA-4（α4β1）相互作用的能力。
• Substituted benzoxazole compounds
  申请人：Aventis Pharma Limited

  公开号：US06593354B2

  公开（公告）日：2003-07-15

  The invention is directed to physiologically active compounds of formula (Ia): wherein R1 is optionally substituted aryl or optionally substituted heteroaryl; R2 is hydrogen, halogen, lower alkyl or lower alkoxy; R3 is alkylene, alkenylene or alkynylene; R5 is hydrogen or lower alkyl; L2 is optionally substituted alkylene or alkenylene; Y is carboxy; and Z1 is NR5; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (&agr;4&bgr;1).

  该发明涉及式(Ia)的生理活性化合物： 其中，R1是可选取代的芳基或可选取代的杂环芳基；R2是氢、卤素、低碳基或低氧基；R3是烷基、烯基或炔基；R5是氢或低碳基；L2是可选取代的烷基或烯基；Y是羧基；Z1是NR5；以及它们的N-氧化物和前药；还有这些化合物及其N-氧化物和前药的药学上可接受的盐和溶剂（例如水合物）。这些化合物具有有价值的药理学特性，尤其是调节VCAM-1和纤维连接蛋白与整合素VLA-4(&agr;4&bgr;1)相互作用的能力。
• BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS
  申请人：Aventis Pharma Limited

  公开号：EP1153017B1

  公开（公告）日：2006-05-03
• US6593354B2
  申请人：——

  公开号：US6593354B2

  公开（公告）日：2003-07-15
• [EN] BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS<br/>[FR] COMPOSES BICYCLIQUES ET LEUR UTILISATION COMME LIGANDS DU RECEPTEUR DE L'INTEGRINE
  申请人：AVENTIS PHARMA LTD

  公开号：WO2000049005A1

  公开（公告）日：2000-08-24

  The invention is directed to physiologically active compounds of general formula (I): wherein Het is an optionally substituted, saturated, partially saturated or fully unsaturated 8 to 10 membered bicyclic ring; R1 is optionally substituted aryl or optionally substituted heteroaryl; R2 is hydrogen, halogen, lower alkyl or lower alkoxy; L1 is an -R3-R4- linkage where R3 is alkylene, alkenylene or alkynylene and R4 is a direct bond, cycloalkylene, heterocycloalkylene, arylene, heteroaryldiyl, -C(=Z?2)-NR5-, -NR5-C(=Z2)-, -Z2¿-, -C(=O)-, -C(=NOR?5)-, -NR5-, -NR5-C(=Z2)-NR5¿-, -SO¿2?-NR?5-, -NR5-SO¿2-, -O-C(=O)-, -C(=O)-O-, -NR5-C(=O)-O- or -O-C(=O)-NR5-; L2 is optionally substituted alkylene or alkenylene; Y is carboxy or an acid bioisostere; and Z?1 is NR5¿; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (α4β1).